Drug Profile
Research programme: mitochondrial inhibitors - MEI Pharma
Alternative Names: ME-128; NV-128Latest Information Update: 12 Dec 2017
Price :
$50
*
At a glance
- Originator Novogen
- Developer MEI Pharma
- Class Isoflavones; Small molecules
- Mechanism of Action MTORC1 protein inhibitors; MTORC2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
- 07 Sep 2012 Preclinical development is ongoing in USA
- 28 Jun 2012 Marshall Edwards is now called MEI Pharma